The information on this page is updated via a feed from the London Stock Exchange's Regulatory News Service.
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
Report of Foreign
Issuer
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of
1934
For February 2009
Commission File
Number: 001-11960
AstraZeneca PLC
15 Stanhope Gate, London W1K 1LN, England
Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form
40-F.
Form 20-F X
Form
40-F __
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7): ______
Indicate by check mark whether the
registrant by furnishing the information contained in this Form is also thereby
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under
the Securities Exchange Act of 1934.
Yes __ No X
If “Yes” is marked, indicate below the
file number assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
AstraZeneca PLC
INDEX TO EXHIBITS
1.
Press release entitled,
“AstraZeneca’s Partner, MAP Pharmaceuticals, announces Phase III study of
Unit Dose Budesonide in children with asthma did not meet primary
endpoints”, dated 24 February
2009.
2.
Press release entitled,
“AstraZeneca to participate in tentative FDA Psychopharmacologic Drugs
Advisory Committee”, dated 25 February
2009.
3.
Press release entitled,
“Transaction by Persons Discharging Managerial Responsibilities Disclosure
Rule DTR 3.1.4”, dated 25 February
2009.
4.
Press release entitled,
“Transaction by Persons Discharging Managerial Responsibilities Disclosure
Rule DTR 3.1.4”, dated 25 February
2009.
5.
Press release entitled,
“Transaction by Persons Discharging Managerial Responsibilities Disclosure
Rule DTR 3.1.4 ”, dated 26 February
2009.
6.
Press release
entitled, “Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4 “, dated 26 February
2009.
7.
Press release
entitled, “Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4”, dated 26 February
2009.
8.
Press release
entitled, “AstraZeneca receives FDA complete response letter on SEROQUEL
XR for Generalised Anxiety Disorder”, dated 27 February
2009.
9.
Press release
entitled, “AstraZeneca PLC Board change”, dated 27 February
2009.
10.
Press release entitled,
“Transparency Directive Voting Rights and Capital”, dated 27 February
2009.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly
authorized.
AstraZeneca
PLC
Date: 3 March
2009
By:
/s/ Justin
Hoskins
Name:
Justin
Hoskins
Title:
Deputy Company
Secretary
Item 1
ASTRAZENECA’S
PARTNER, MAP PHARMACEUTICALS, ANNOUNCES PHASE III STUDY OF UNIT DOSE BUDESONIDE
IN CHILDREN WITH ASTHMA DID NOT MEET PRIMARY ENDPOINTS
MAP
Pharmaceuticals, Inc. announced yesterday that its initial Phase III clinical
trial of Unit Dose Budesonide (UDB) for the potential treatment of children with
asthma did not meet its co-primary endpoints: asthma control as assessed by
changes from baseline in night-time and daytime composite symptom scores, in
either of the doses evaluated when compared with placebo.
AstraZeneca will
work with MAP Pharmaceuticals to conduct further analyses of these data to
determine appropriate next steps for the programme.
AstraZeneca and MAP
Pharmaceuticals have a collaboration agreement to develop and commercialise
UDB.
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in the research, development,
manufacturing and marketing of meaningful prescription medicines and supplier
for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infectious disease medicines. For more information about
AstraZeneca, please visit: www.astrazeneca.com
About
MAP Pharmaceuticals
MAP Pharmaceuticals
is dedicated to developing and commercialising new therapies for children and
adults suffering from chronic conditions that are not adequately treated by
currently available medicines. The company has two product candidates in Phase
III clinical development. Unit Dose Budesonide is being developed in
collaboration with AstraZeneca for the potential treatment of asthma in
children, and MAP0004 is being developed for the potential treatment of
migraine. In addition, MAP Pharmaceuticals generates new pipeline opportunities
by applying its proprietary drug particle and inhalation technologies to enhance
the therapeutic benefits of proven drugs, while minimising risk, by capitalising
on their known safety, efficacy and commercialisation
history. Additional information about MAP Pharmaceuticals can be
found at www.mappharma.com
Media
Enquiries UK:
Chris
Sampson
+44 20 7304
5130 (24 hours)
Neil
McCrae
+44 20 7304
5045 (24 hours)
Sarah
Lindgreen
+44 20 7304
5033 (24 hours)
Media
Enquiries US:
Emily
Denney
+1 302 885
3451
mob: +1 302
897 4953
Investor
Enquiries UK:
Jonathan
Hunt
+44 207 304
5087
mob: +44 7775
704032
Karl
Hard
+44 207 304
5322
mob: +44 7789
654364
Investor
Enquiries US:
Ed
Seage
+1 302 886
4065
mob: +1 302
373 1361
Jorgen
Winroth
+1 212 579
0506
mob: +1 917
612 4043
24
February 2009
- ENDS
-
Item 2
ASTRAZENECA
TO PARTICIPATE IN TENTATIVE FDA PSYCHOPHARMACOLOGIC DRUGS ADVISORY
COMMITTEE
AstraZeneca has
been informed that the U.S. Food and Drug Administration (FDA)
Psychopharmacologic Drugs Advisory Committee (PDAC) has been tentatively
scheduled to meet on 8 April 2009. AstraZeneca has been advised that at its
meeting, the PDAC will discuss the safety and efficacy of supplemental new drug
applications (sNDA) for SEROQUEL XR proposed for the treatment of major
depressive disorder (MDD) and generalised anxiety disorder (GAD).
AstraZeneca fully
supports the work of the FDA in conducting a full review of the potential
benefits and risks of SEROQUEL XR in the treatment of major depressive disorder
and generalised anxiety disorder.
SEROQUEL XR, a
once-daily, extended release formulation of SEROQUEL, was approved in the U.S.
in 2007 for the acute and maintenance treatment of schizophrenia in adult
patients and in October 2008 for the acute treatment of the depressive episodes
associated with bipolar disorder, the manic and mixed episodes associated with
bipolar I disorder, and the maintenance treatment of bipolar I disorder as
adjunctive therapy to lithium or divalproex. These FDA approved
indications are not scheduled to be part of this PDAC meeting.
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in the research, development,
manufacturing and marketing of meaningful prescription medicines and supplier
for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infectious disease medicines. For more information about
AstraZeneca, please visit: www.astrazeneca.com
Media
Enquiries UK:
Chris
Sampson
+44 20 7304
5130 (24 hours)
Neil
McCrae
+44 207 304
5045 (24 hours)
Sarah
Lindgreen
+44 20 7304
5033 (24 hours)
Media
Enquiries US:
Michele
Meeker
+1 302 885
6351
Kirsten
Evraire
+1 302 885
0435
Investor
Enquiries UK:
Jonathan
Hunt
+44 207 304
5087
mob: +44 7775
704032
Karl
Hard
+44 207 304
5322
mob: +44 7789
654364
Investor
Enquiries US:
Ed
Seage
+1 302 886
4065
mob: +1 302
373 1361
Jorgen
Winroth
+1 212 579
0506
mob: +1 917
612 4043
25
February 2009
- ENDS
-
Item 3
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that on 24 February 2009, the interest of the following individuals, who are
all persons discharging managerial responsibilities, in AstraZeneca PLC Ordinary
Shares of $0.25 each, changed as detailed below. The change in
interest relates to the vesting of previously announced awards made in February
2006 under the AstraZeneca Deferred Bonus Plan whereby the individuals concerned
have now become beneficially entitled to the shares. In each case,
sufficient shares were withheld to cover certain tax obligations arising on the
vesting.
Name
Number of
Shares Vested
Number of
Shares Withheld
Net Number of
Shares
Bruno
Angelici
2,448
1,004
1,444
Jan
Lundberg
2,059
1,195
864
The closing market
price of AstraZeneca PLC Ordinary Shares of $0.25 each on 24 February 2009 was
2415 pence.
A
C N Kemp
Company
Secretary
25
February 2009
Item 4
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that on 24 February 2009, the interest of the following Directors in
AstraZeneca PLC Ordinary Shares of $0.25 each changed as detailed
below. The change in interest relates to the vesting of previously
announced awards made in February 2006 under the AstraZeneca Deferred Bonus Plan
whereby the individuals concerned have now become beneficially entitled to the
shares. In each case, sufficient shares were withheld to cover
certain tax obligations arising on the vesting.
Name of
Director
Number of
Shares
Vested
Number of
Shares
Withheld
Net Number
of
Shares
Current
Holding
Percentage of
Issued Share
Capital
David R
Brennan
6,352
2,605
3,747
See
below
See
below
John
Patterson
6,623
2,716
3,907
152,446
0.01%
Mr Brennan has
interests in both the Ordinary Shares and the American Depositary Shares (ADSs)
of AstraZeneca PLC. One ADS equals one Ordinary Share.
As a result of this
transaction, Mr Brennan’s interest is now 393,369 Ordinary Shares and 116,689
AstraZeneca ADSs, which together represent approximately 0.035% of the Company’s
issued ordinary capital.
The closing market
price of AstraZeneca PLC Ordinary Shares of $0.25 each on 24 February 2009 was
2415 pence.
A
C N Kemp
Company
Secretary
25
February 2009
Item 5
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that on 25 February 2009, the following Directors acquired an interest in
the USD0.25 Ordinary Shares of AstraZeneca PLC. The interest arises
as a result of the previously disclosed arrangements relating to the payment of
annual bonuses for 2008 whereby each individual is required to defer a portion
of the bonus earned into shares for a period of three years. The
shares were allocated at a price of 2400 pence per share. The
individuals will become beneficially entitled to these shares on 25 February
2012.
Name
Number of
shares allocated
Total
interest in shares after this allocation
Percentage of
shares in issue
S
Lowth
9,775
85,967
0.006%
J S
Patterson
7,256
159,702
0.011%
A
C N Kemp
Company
Secretary
26
February 2009
Item 6
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that the interest of David R. Brennan, a Director of the Company, in the
shares of AstraZeneca PLC has changed as detailed below. Mr Brennan
has interests in both the Ordinary Shares and the American Depositary Shares
(ADSs) of AstraZeneca PLC. One ADS equals one Ordinary
Share.
On 25 February
2009, Mr Brennan received an allocation of 17,992 Ordinary Shares under the
previously disclosed arrangements relating to his annual bonus for 2008 whereby
he is required to defer a portion of the bonus earned into shares for a period
of three years. The shares were allocated at a price of 2400 pence
per share. Mr Brennan will become beneficially entitled to these
shares on 25 February 2012.
On 25 February
2009, Mr Brennan received scheduled distributions out of the AstraZeneca US
Executive Deferral Plan and the AstraZeneca US Executive Deferred Compensation
Plan, unitised stock funds established in 2000 and 2005 respectively, in which
Mr Brennan, in common with other participating US executives, is deemed to have
a notional interest in ADSs calculated by reference to the fund value and the
closing price of AstraZeneca ADSs. Following this scheduled
distribution on 25 February 2009, Mr Brennan had a notional interest in 36,105
ADSs within the AstraZeneca US Executive Deferral Plan by reference to the
closing price of ADSs on 25 February 2009 of US$33.95. Mr Brennan’s interest in
ADSs within the AstraZeneca US Executive Deferred Compensation Plan has reduced
to zero as a result of this distribution.
Immediately prior
to the above transactions, Mr Brennan had an interest in 393,369 Ordinary Shares
and 116,689 AstraZeneca ADSs. As a result of these transactions, Mr
Brennan’s interest is now 411,361 Ordinary Shares and 76,364 AstraZeneca ADSs,
including the notional interest in ADSs in the AstraZeneca US Executive Deferral
Plan referred to above. This interest represents approximately 0.034%
of the Company’s issued ordinary capital.
A
C N Kemp
Company
Secretary
26
February 2009
Item 7
Transaction
by Persons Discharging Managerial Responsibilities
Disclosure
Rule DTR 3.1.4
We hereby inform
you that on 25 February 2009, the following individuals, who are all persons
discharging managerial responsibilities, acquired an interest in the USD0.25
Ordinary Shares of AstraZeneca PLC or, in the case of L Tetrault and A Zook, in
the Company’s American Depositary Shares (ADSs). One ADS equals one
Ordinary Share. The interest arises as a result of the previously
disclosed arrangements relating to the payment of annual bonuses for 2008
whereby each individual is required to defer a portion of the bonus earned into
shares for a period of three years. The shares are awarded under the
terms of the AstraZeneca Deferred Bonus Plan. The individuals will
become beneficially entitled to these shares on 25 February 2012.
Name
Number of
shares
allocated
Award price
per
share
B
Angelici
2,680
2400p
J
Lundberg
2,593
2400p
D
Smith
2,535
2400p
L
Tetrault
3,432
US$33.95
A
Zook
5,050
US$33.95
A
C N Kemp
Company
Secretary
26
February 2009
Item 8
ASTRAZENECA
RECEIVES FDA COMPLETE RESPONSE LETTER ON SEROQUEL XR FOR GENERALISED ANXIETY
DISORDER
AstraZeneca today
announced the company has received a Complete Response Letter (CRL) from the
U.S. Food and Drug Administration (FDA) asking for additional information for
the supplemental New Drug Application (sNDA) for SEROQUEL XR (quetiapine
fumarate) Extended Release Tablets for the treatment of Generalised Anxiety
Disorder (GAD) in adult patients.
AstraZeneca is
evaluating the contents of the CRL and the proposed labelling
revisions. AstraZeneca announced on 25 February 2009 that the company
had been advised by the FDA that the Psychopharmacologic Drugs Advisory
Committee (PDAC) is tentatively scheduled to meet on 8 April 2009 to discuss the
safety and efficacy of sNDAs for SEROQUEL XR proposed for the treatment of major
depressive disorder (MDD) and GAD.
An update to
AstraZeneca investors will be provided when appropriate.
SEROQUEL XR, a
once-daily, extended release formulation of SEROQUEL (quetiapine fumarate), was
approved in the U.S. in 2007 for the acute and maintenance treatment of
schizophrenia in adult patients and in October 2008 for the acute treatment of the depressive
episodes associated with bipolar disorder, the manic and mixed episodes associated with
bipolar I disorder, and the maintenance treatment of bipolar I disorder as
adjunctive therapy to lithium or divalproex. The CRL does not
change the current recommendations for the treatment of patients taking SEROQUEL
XR or SEROQUEL for approved indications in schizophrenia and bipolar
disorder.
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in the research, development,
manufacturing and marketing of meaningful prescription medicines and supplier
for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infectious disease medicines. For more information about
AstraZeneca, please visit: www.astrazeneca.com
Media
Enquiries UK:
Chris
Sampson
+44 20 7304
5130 (24 hours)
Neil
McCrae
+44 207 304
5045 (24 hours)
Sarah
Lindgreen
+44 20 7304
5033 (24 hours)
Media
Enquiries US:
Kirsten
Evraire
+1 302 885
0435
Abigail
Baron
+1 302 885
3578
Investor
Enquiries UK:
Jonathan
Hunt
+44 207 304
5087
mob: +44 7775
704032
Karl
Hard
+44 207 304
5322
mob: +44 7789
654364
Investor
Enquiries US:
Ed
Seage
+1 302 886
4065
mob: +1 302
373 1361
Jorgen
Winroth
+1 212 579
0506
mob: +1 917
612 4043
27
February 2009
- ENDS
-
Item 9
ASTRAZENECA
PLC BOARD CHANGE
AstraZeneca today
announced that Håkan Mogren, Non-Executive Deputy Chairman of AstraZeneca PLC,
will retire from the Board at the close of the company’s AGM on 30 April
2009.
Louis Schweitzer,
Chairman of AstraZeneca PLC, said: “As Chief Executive Officer of Astra AB, and
subsequently Deputy Chairman of AstraZeneca, Håkan has made an excellent
contribution to our business. He was instrumental in the formation of
AstraZeneca and has brought a wealth of experience and sound judgement to our
Board decisions. His fellow Directors and I thank him for his
distinguished contribution to the company over two decades and wish him a long
and very happy retirement.”
About
AstraZeneca
AstraZeneca is a
major international healthcare business engaged in the research, development,
manufacturing and marketing of meaningful prescription medicines and supplier
for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infectious disease medicines. For more information about
AstraZeneca, please visit: www.astrazeneca.com
Media
Enquiries UK:
Chris
Sampson
+44 20 7304
5130 (24 hours)
Neil
McCrae
+44 207 304
5045 (24 hours)
Sarah
Lindgreen
+44 20 7304
5033 (24 hours)
Investor
Enquiries UK:
Jonathan
Hunt
+44 207 304
5087
mob: +44 7775
704032
Karl
Hard
+44 207 304
5322
mob: +44 7789
654364
Investor
Enquiries US:
Ed
Seage
+1 302 886
4065
mob: +1 302
373 1361
Jorgen
Winroth
+1 212 579
0506
mob: +1 917
612 4043
27
February 2009
- ENDS
-
Item 10
Transparency
Directive
Voting
Rights and Capital
The following
notification is made in accordance with the UK Financial Services Authority
Disclosure and Transparency Rule 5.6.1. On 27 February 2009 the
issued share capital of AstraZeneca PLC with voting rights is 1,447,644,517
ordinary shares of US$0.25. No shares are held in Treasury.
Therefore, the total number of voting rights in AstraZeneca PLC is
1,447,644,517.
The above figure
for the total number of voting rights may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in,
AstraZeneca PLC under the FSA's Disclosure and Transparency Rules.
A
C N Kemp
Company
Secretary
27
February 2009
